The American Society of Clinical Oncology’s annual meeting begins this week, including the presentation of more than 2,800 abstracts. Amgen, Roche, and Sierra Oncology are among the companies with key presentations at this year’s gathering.
Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other cell therapies. The company now has early Phase 1 data that bring some validation to the approach.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Judges picked TrialSpark as the winner on the life sciences track of the pitch competition at MedCity's virtual precision medicine conference. While the company is focused on improving clinical trials for others, it hopes eventually to bring drugs of its own to market.
At the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day in New York Thursday, industry insiders gathered to talk about CAR-Ts in solid tumor cancers.
The company also just acquired Israel-based Applied Immune Technologies, meant to fine tune its development of monoclonal antibodies.